Antabio Awarded $4.4M for Continued Research for P. aeruginosa Lung Infection Therapy Jan 08, 2020 07:00 am | Vanessa Pataia

https://cysticfibrosisnewstoday.com/2020/01/08/antabio-awarded-4-4-million-continued-research-pseudomonas-aeruginosa-lung-infection-therapy-cf-patients/?utm_source=Cystic+Fibrosis&utm_campaign=3d1c9651d9-RSS_MONDAY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b075749015-3d1c9651d9-72020733

Antabio Awarded $4.4M for Continued Research for P. aeruginosa Lung Infection Therapy

Jan 08, 2020 07:00 am | Vanessa Pataia

Biopharmaceutical company Antabio has been awarded $4.4 million by CARB-X to continue its research for a therapy against Pseudomonas aeruginosa lung infections in people with cystic fibrosis (CF). The funding will be used to support Antabio’s Pseudomonas Elastase Inhibitor (PEi) program, which is seeking to develop a small molecule to stop the action of the […] The post Antabio Awarded $4.4M for Continued Research for P. aeruginosa Lung Infection Therapy appeared first on Cystic Fibrosis News Today.

Read More